Navigation Links
Study shows interruption of antiretroviral therapy increases risk of disease and death

Findings from one of the largest HIV/AIDS therapy studies conducted to date show that a specific strategy of interrupting antiretroviral therapy more than doubles the risk of AIDS or death from any cause. Researchers affiliated with the Mailman School of Public Health and Harlem Hospital Hospital led a large multi-center international study, known as Strategies for Management of Anti-Retroviral Therapies, or SMART, comparing two treatment strategies for people with human immunodeficiency virus (HIV). Findings from the study, published in the November 30 New England Journal of Medicine, demonstrate the value of continuous antiretroviral therapy.

As HIV/AIDS has evolved into a chronic disease without a cure, lifelong antiretroviral therapy has become the norm. Lifelong therapy, however, can be difficult to adhere to as well as expensive. For these reasons, there has been a concerted research effort to test treatment interruption strategies that may enhance patients' quality of life and limit adverse drug effects.

The strategies evaluated in the SMART Study compared the recommended continuous use of antiretroviral therapy (anti-HIV medicines) with use of antiretroviral therapy in an episodic (interrupted) manner. The study found that the use of episodic antiretroviral therapy was inferior to continuous therapy as episodic therapy significantly increased the risk of opportunistic diseases or death from any cause. Further, episodic antiretroviral therapy did not reduce the risk of serious complications, including those related to the heart, kidneys, and liver.

Antiretroviral therapy in people with HIV is associated with remarkable benefits including longer survival and less illness. However, life-long treatment is difficult and can be associated with both short- and long-term risks, such as major metabolic and cardiovascular complications and built-up resistance to treatment. According to Wafaa El-Sadr, MD, MPH, co-chair of the SMART Study and p
'"/>

Source:Columbia University's Mailman School of Public Health


Page: 1 2 3

Related biology news :

1. Novel Asthma Study Shows Multiple Genetic Input Required; Single-gene Solution Shot Down
2. Emory Study Tests Bone Marrow Stem Cells to Improve Circulation in Legs
3. UCLA Study Shows One-Third of Drug Ads in Medical Journals Do Not Contain References Supporting Medical Claims
4. Study Demonstrates Gene Expression Microarrays are Comparable and Reproducible
5. Study Links Ebola Outbreaks To Animal Carcasses
6. Breakthrough Microarray-based Technology for the Study of Cancer
7. NYU Study Reveals How Brains Immune System Fights Viral Encephalitis
8. Study finds more than one-third of human genome regulated by RNA
9. Leukemia Drug Breakthrough Study In New England Journal Of Medicine
10. Study identifies predictors of HIV drug resistance in patients beginning triple therapy
11. New Study from Affymetrix Laboratories Points to Changing View of How Genome Works

Post Your Comments:
(Date:12/1/2009)...ash University-led international research team has...f the next generation of solar cells. , Scientis...leagues from the universities of Wollongong and Ul...solar cells with a three-fold increase in energy c...rted tandem dye-sensitised solar cells. , Lead ...
(Date:12/1/2009)...s an ,abominable mystery, and it is a question whi... when did flowering plants evolve and how did they...dy in Ecology Letters reveals the evolutionary t... a major competitive advantage over rival species,..., The study, by Dr Tim Brodribb and Dr Taylor Fi...
(Date:12/1/2009)...cold, can spread among groups of people, research ...lifornia-San Diego and Harvard shows., Using lon...een following health conditions for more than 60 y...tend to share their loneliness with others. Gradua...ple moves to the fringes of social networks., We...
Breaking Biology News(10 mins):Innovation puts next-generation solar cells on the horizon 2How did flowering plants evolve to dominate Earth? 2Loneliness can be contagious 2Loneliness can be contagious 3Echo Therapeutics and Handok Pharmaceuticals Sign South Korea License for Needle free Symphony 28TM 29 Transdermal Continuous Glucose Monitoring Syste 49185 1Echo Therapeutics and Handok Pharmaceuticals Sign South Korea License for Needle free Symphony 28TM 29 Transdermal Continuous Glucose Monitoring Syste 49185 2Echo Therapeutics and Handok Pharmaceuticals Sign South Korea License for Needle free Symphony 28TM 29 Transdermal Continuous Glucose Monitoring Syste 49185 3Echo Therapeutics and Handok Pharmaceuticals Sign South Korea License for Needle free Symphony 28TM 29 Transdermal Continuous Glucose Monitoring Syste 49185 4Arena Pharmaceuticals to Receive 24100 Million from Deerfield Management 49183 1Arena Pharmaceuticals to Receive 24100 Million from Deerfield Management 49183 2Arena Pharmaceuticals to Receive 24100 Million from Deerfield Management 49183 3Arena Pharmaceuticals to Receive 24100 Million from Deerfield Management 49183 4This Fathers Day Give Dad a Gift Straight for the Heart 49181 1This Fathers Day Give Dad a Gift Straight for the Heart 49181 2This Fathers Day Give Dad a Gift Straight for the Heart 49181 3
...indings for the future,of California tiger salaman...hought about what happens when animal species inte...student Benjamin Fitzpatrick,(now on the faculty o...r Bradley Shaffer, was published recently in the P...line edition. , The salamander experts studied th...
... Inc., announced today that it has been awarded a ...ited States Defense Threat Reduction Agency (DTRA)...nners of this award were selected after an intense...academic, government, and industrial labs. , Nano...nostics, have been privately developing Gene-RADAR...
...million gift to the University of Michigan Health ...institute one with a mission of supporting fundam... causes, treatment and prevention of a broad range...al Research Institute, being established in the U-...whose funding and vision led to its creation. Mr. ...
Other Biology News:Nanobiosym awarded $2 million DTRA contract 2$22 million gift from Alfred Taubman launches new biomedical research institute 2$22 million gift from Alfred Taubman launches new biomedical research institute 3$22 million gift from Alfred Taubman launches new biomedical research institute 4
(Date:12/1/2009)...VER, British Columbia, Dec. 1 /PRNewswire-FirstCal...ary of The Dow Chemical Company (NYSE: DOW ), an...igning of a research and commercial license option...s with access to Agrisoma,s proprietary Engineered... in major food crops, and on a non-exclusive basis...
(Date:12/1/2009)...FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Bo...harmaceutical company developing human vaccines fo... Virus) and other infectious agents, today announc... the 21st World AIDS Day and as we remember the mi...S pandemic, we remain focused and devoted to comme...
(Date:12/1/2009)...vides services to three out of top five ,global ph... Rochester, NY (PRWEB) December 1, 2009 -- iCardia...cardiac core lab services and QT analysis, announc...s selected iCardiac as a preferred vendor of ECG c...tomated QT(sm) and Dynamic QT beat-to-beat(sm) ser...
(Date:11/30/2009)... international team of applied scientists from Har...nstrated compact, multibeam, and multi-wavelength ... spectrum (infrared). By contrast, typical lasers ...gth. The innovative multibeam lasers have potentia...ensing pollution monitoring, optical wireless, and...
Breaking Biology Technology:Dow AgroSciences, Agrisoma Biosciences Announce Research and Commercial License Option Agreement for Agricultural Crops 2Dow AgroSciences, Agrisoma Biosciences Announce Research and Commercial License Option Agreement for Agricultural Crops 3GeoVax Labs, Inc. Celebrates 21st World AIDS Day With Continued Clinical Trial Progress 2GeoVax Labs, Inc. Celebrates 21st World AIDS Day With Continued Clinical Trial Progress 3GeoVax Labs, Inc. Celebrates 21st World AIDS Day With Continued Clinical Trial Progress 4GeoVax Labs, Inc. Celebrates 21st World AIDS Day With Continued Clinical Trial Progress 5GeoVax Labs, Inc. Celebrates 21st World AIDS Day With Continued Clinical Trial Progress 6Another Top Five Pharmaceutical Company Selects iCardiac as Preferred Provider of ECG Core Lab Services 2Scientists demonstrate multibeam, multi-functional lasers 2
Modine Manufacturing earnings drop
... Alliance, a group of investors, scientists and po... annual report that it is creating a roadmap for a...the area. , ,Founded in 2004, the alliance receive...rticipating academic institutions. That was not qu...ginally proposed, and which the alliance is still ...
...e these days, thanks to record oil prices and the ...ld be enhanced by producing more energy at home. W...e energy potential of crops such as corn, a quiet ...enetically engineered crops. , ,About 8.5 million...222 million acres in 2005, up 11 percent over the ...
Other Biology Technology:Biotech crops gaining acceptance, but their full promise has yet to be fulfilled 2Biotech crops gaining acceptance, but their full promise has yet to be fulfilled 3
BspT107 I (HgiC I, Ban I) from Takara Mirus Bio
Bsu36 I from Promega
Mouse Anti-Verotoxin IIbeta Monoclonal Antibody, Unconjugated, Clone 457 from Santa Cruz Biotechnology, Inc.
Multiskan EX from Thermo Scientific
Biology Products: